Janssen Launching Phase 1 Trial Testing VE202 for Potential IBD Treatment

Janssen Launching Phase 1 Trial Testing VE202 for Potential IBD Treatment
Janssen Biotech will conduct a Phase 1 clinical trial in healthy volunteers to test VE202, an investigational oral treatment for inflammatory bowel disease (IBD), Vedanta Biosciences has announced. In 2015, Janssen bought the rights from Vedanta for VE202, an oral live biotherapeutic product (a treatment consisting of living microorganisms) that contains a curated mix of bacteria usually present in healthy individuals. The launch of the study comes with a payment of $12 million from Janssen — a
Subscribe or to access all post and page content.